Unicycive Q3 net loss $6.0M, cash $42.7M; plans OLC NDA resubmission by year-end 2025

Unicycive Therapeutics, Inc.

2025-Q3 EPS reported -$0.85 vs consensus -$0.57 ▼ miss (-49.7%)

Net loss of $6.0M for Q3 2025 vs $4.1M in Q3 2024; cash $42.7M as of Sept 30, 2025, with runway into 2027.
On track to resubmit NDA for oxylanthanum carbonate (OLC) by year-end 2025 after positive FDA Type A meeting; potential PDUFA in H1 2026.
Presented OLC data at ASN Kidney Week showing 7x reduction in pill volume and 2x reduction in pill count vs current binders.
R&D expenses flat at $3.0M; G&A increased to $4.4M from $3.2M due to higher labor and consulting costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.